- Home
- CMPS vs RIGL Comparison
CMPS vs RIGL Comparison
Compare CMPS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | RIGL |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.5M | 628.4M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CMPS | RIGL |
|---|---|---|
| Price | $5.76 | $31.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $26.57 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.8M | 277.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $1.54 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $2.25 | $16.05 |
| 52 Week High | $8.90 | $52.24 |
Technical Indicators
Market Signals| Indicator | CMPS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 61.93 |
| Support Level | $4.90 | $28.08 |
| Resistance Level | $7.02 | $31.92 |
| Average True Range (ATR) | 0.28 | 1.12 |
| MACD | 0.07 | 0.76 |
| Stochastic Oscillator | 71.76 | 98.44 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.